Last reviewed · How we verify

NCT06718478

First in Human Study of SakuraBead for Genicular Artery Embolization to Treat Pain Secondary to Knee Osteoarthritis

Completed NA Last updated 5 December 2024
What this trial tests

NA trial testing SakuraBead Resorbable Microspheres in Osteoarthritis (OA) of the Knee in 15 participants. Completed in 23 August 2024.

Timeline
5 December 2023
Primary endpoint
28 March 2024
23 August 2024

Quick facts

Lead sponsorCrannMed
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date5 December 2023
Primary completion28 March 2024
Estimated completion23 August 2024
Sites1 location across Uzbekistan

Drugs / interventions tested

Conditions studied

Sponsor

CrannMed — full company profile →

Who can join

40 and older, any sex, with Osteoarthritis (OA) of the Knee or Osteoarthritis Knee Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, single-centre, single-arm, unmasked, First in Human study that aims to evaluate the safety and efficacy of SakuraBead resorbable microspheres in adult patients suffering from pain secondary to knee osteoarthritis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Osteoarthritis (OA) of the Knee

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06718478.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing